Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development. Its advanced program is its therapeutic MM-398, which it markets in the United States under the brand name ONIVYDE. Its other clinical stage product candidates include MM-121, MM-141, MM-310, MM-302 and MM-151. The Company is developing in vitro and in vivo diagnostics for use with each of its oncology therapeutic product candidates. Its in vitro diagnostic agents employ biophysical or biochemical markers of cancer, or biomarkers. Its in vivo diagnostics take the form of imaging agents that may help identify patients likely to benefit from its therapeutic products by measuring deposition of its products in the tumor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MACK
  • CUSIP: 59032810
  • Web:
  • Market Cap: $180.1 million
  • Outstanding Shares: 132,741,000
Average Prices:
  • 50 Day Moving Avg: $1.34
  • 200 Day Moving Avg: $2.69
  • 52 Week Range: $1.13 - $6.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.09
  • P/E Growth: -0.43
Sales & Book Value:
  • Annual Revenue: $144.27 million
  • Price / Sales: 1.25
  • Book Value: ($2.09) per share
  • Price / Book: -0.65
  • EBIDTA: ($88,040,000.00)
  • Net Margins: -105.18%
  • Return on Assets: -135.72%
  • Debt-to-Equity Ratio: -0.79%
  • Current Ratio: 0.43%
  • Quick Ratio: 0.43%
  • Average Volume: 3.03 million shs.
  • Beta: 2.03
  • Short Ratio: 5.24
Frequently Asked Questions for Merrimack Pharmaceuticals (NASDAQ:MACK)

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals declared an annual dividend on Friday, April 7th. Stockholders of record on Wednesday, May 17th will be paid a dividend of $1.06 per share on Friday, May 26th. The ex-dividend date is Tuesday, May 30th. View Merrimack Pharmaceuticals' Dividend History.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.15. During the same quarter in the prior year, the business posted ($0.33) earnings per share. View Merrimack Pharmaceuticals' Earnings History.

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1-year target prices for Merrimack Pharmaceuticals' shares. Their predictions range from $5.00 to $13.00. On average, they expect Merrimack Pharmaceuticals' share price to reach $8.33 in the next year. View Analyst Ratings for Merrimack Pharmaceuticals.

What are analysts saying about Merrimack Pharmaceuticals stock?

Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "With the sale of Onivyde, Merrimack is back to being a development-stage biopharmaceutical company. Thus, the successful development of the three lead candidates in its pipeline is critical for Merrimack’s growth. Moreover, two of the candidates, MM-121 and MM-141, are still being evaluated in phase II studies. And the third candidate, MM-310 entered phase I study in the first quarter of 2017. Also, shares of the company have underperformed the Zacks categorized Medical Biomed/Genetics industry year to date. However, the cash received from Ipsen will be used to pay down the huge debt and return value to shareholders in the form of dividends. Estimates have remained mostly stable lately ahead of the Q2 results. The company has a mixed record of earnings surprises in recent quarters." (7/17/2017)
  • 2. J P Morgan Chase & Co analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a increase in short interest in July. As of July 14th, there was short interest totalling 25,683,568 shares, an increase of 2.1% from the June 30th total of 26,222,342 shares. Based on an average trading volume of 1,788,334 shares, the days-to-cover ratio is currently 14.4 days. Currently, 20.5% of the shares of the stock are short sold.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:

  • Gary L. Crocker, Chairman of the Board
  • Richard Peters M.D., Ph.D., President, Chief Executive Officer, Principal Financial Officer, Director
  • John L. Green, Chief Accounting Officer, Controller
  • Ellen K. Forest, Head of Human Resources
  • Sergio L. Santillana, Chief Medical Officer
  • Ulrik B. Nielsen Ph.D., Director
  • John M. Dineen, Independent Director
  • Vivian S. Lee, Independent Director
  • John Mendelsohn M.D., Independent Director
  • Michael E. Porter Ph.D., Independent Director

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Kempner Capital Management Inc. (0.11%), Clear Harbor Asset Management LLC (0.11%) and Creative Planning (0.07%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond, Edward J Stewart, Michael E Porter, Vivian S Lee and William M Mcclements. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Clear Harbor Asset Management LLC and Creative Planning. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $1.36.

MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  169 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $8.33 (512.75% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cowen and CompanyReiterated RatingMarket PerformLowView Rating Details
1/11/2017Robert W. BairdReiterated RatingNeutral$5.00N/AView Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$7.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00N/AView Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00N/AView Rating Details
12/30/2015Oppenheimer Holdings, Inc.Reiterated RatingBuyN/AView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Earnings History by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.07)($0.22)$32.16 millionViewN/AView Earnings Details
3/1/2017Q416($0.21)($0.25)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($0.27)($0.23)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015Q1 2015($0.30)($0.32)$14.50 million$14.84 millionViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)$25.13 million$33.91 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.12)($0.27)$61.50 million$28.00 millionViewN/AView Earnings Details
8/11/2014Q2 2014($0.32)($0.17)$10.83 million$27.82 millionViewN/AView Earnings Details
5/1/2014Q114($0.31)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.65 EPS


Dividend History by Quarter for Merrimack Pharmaceuticals (NASDAQ MACK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 8.53%
Institutional Ownership Percentage: 59.22%
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Trades by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/12/2017Daryl C DrummondInsiderSell4,097$3.72$15,240.84View SEC Filing  
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Merrimack Pharmaceuticals (NASDAQ:MACK)
Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateHeadline logoMerrimack Appoints Thomas Needham as Chief Business Officer - PR Newswire (press release) - July 24 at 12:43 PM logoMerrimack Appoints Thomas Needham as Chief Business Officer - July 24 at 12:42 PM logoEx-Akebia Employee Faces Losing Bail in Insider Trading Case - New York Times - July 22 at 6:15 AM logoMerrimack Pharmaceuticals, Inc. (MACK) Receives Consensus Rating of "Hold" from Analysts - July 18 at 3:11 PM logoMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Upgraded to "Hold" by Zacks Investment Research - July 17 at 2:52 PM logoMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Short Interest Down 19.9% in June - July 15 at 7:22 AM logoZacks Investment Research Downgrades Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) to Sell - July 11 at 4:10 PM logoTechnical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health - June 29 at 1:11 AM logoTechnical Snapshots for These Biotech Stocks -- Merrimack Pharma, MannKind, GlycoMimetics, and Radius Health - PR Newswire (press release) - June 28 at 7:43 AM logoShort Interest in Merrimack Pharmaceuticals, Inc. (MACK) Rises By 39.7% - June 28 at 7:02 AM logoMerrimack Pharmaceuticals, Inc. (MACK) Receives Average Rating of "Hold" from Analysts - June 23 at 12:37 PM logoKey Pharma Stocks With Advanced Developments and Breakthrough Discoveries - June 21 at 7:30 PM logoMerrimack Pharma (MACK) Completes Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 - June 19 at 11:43 AM logoMerrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018 - June 19 at 11:43 AM logoBRIEF-Merrimack Pharmaceuticals says Richard Peters to be principal financial officer - Reuters - June 16 at 7:21 PM logoWhy Is Merrimack (MACK) Down 57.6% Since the Last Earnings Report? - June 14 at 9:55 AM logoMerrimack Pharmaceuticals Inc (MACK) Short Interest Update - June 11 at 12:46 PM logoMerrimack Pharma (MACK) Names Sergio Santillana as CMO - - June 8 at 7:21 PM logoMerrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources - June 8 at 10:30 AM logoMerrimack Pharmaceuticals Inc (MACK) Downgraded by ValuEngine to "Strong Sell" - June 4 at 8:50 AM logoWhy Merrimack Pharmaceuticals Stock Is Tanking Today - Motley Fool - June 1 at 7:14 PM logoAs Merrimack shares hit new low, CEO vows to stay the course - Boston Business Journal - June 1 at 7:14 PM logoWhy Merrimack Pharmaceuticals Stock Is Tanking Today - May 31 at 11:25 AM logoMerrimack Pharmaceuticals Inc (MACK) Receives Consensus Rating of "Hold" from Analysts - May 29 at 12:47 PM logoMerrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017 - Nasdaq - May 26 at 7:13 PM logoMerrimack Pharma (MACK) CFO Resigns - May 26 at 3:36 AM logoMerrimack Announces Management Change - May 26 at 3:36 AM logoMerrimack Pharmaceuticals Inc (mack) to Issue Annual Dividend of $1.06 - May 25 at 2:27 PM logoMerrimack Pharmaceuticals Inc (MACK) Given "Market Perform" Rating at Cowen and Company - May 19 at 10:18 PM logoMerrimack Pharmaceuticals Inc (MACK) Upgraded to Hold at Zacks Investment Research - May 15 at 12:24 PM logoInsider Selling: Merrimack Pharmaceuticals Inc (MACK) Insider Sells 4,097 Shares of Stock - May 12 at 8:26 PM logoEdited Transcript of MACK earnings conference call or presentation 10-May-17 12:30pm GMT - May 11 at 6:56 PM logoMerrimack (MACK) Q1 Loss Wider than Expected, Sells Onivyde - May 11 at 6:56 PM
News IconBRIEF-Merrimack reports Q1 loss per share $0.23 - May 11 at 4:03 AM logoMerrimack Reports First Quarter 2017 Financial Results - PR Newswire (press release) - May 10 at 5:58 PM logoMerrimack Pharmaceuticals Inc (MACK) Releases Earnings Results, Misses Expectations By $0.11 EPS - May 10 at 3:52 PM logoMerrimack's (MACK) Reports Wider-than-Expected Q1 Loss - May 10 at 12:41 PM logoEarnings Reaction History: Merrimack Pharmaceuticals Inc, 36.4% Follow-Through Indicator, 4.2% Sensitive - May 10 at 12:41 PM logoMerrimack Reports First Quarter 2017 Financial Results - May 10 at 12:41 PM logoInvestor Network: Merrimack Pharmaceuticals, Inc. to Host Earnings Call - May 10 at 12:41 PM logoMerrimack's (MACK) Reports Wider-than-Expected Q1 Loss - May 10 at 12:41 PM logoMerrimack reports 1Q loss - May 10 at 7:04 AM logoMerrimack Pharmaceuticals (MACK) Receiving Somewhat Negative Press Coverage, Study Finds - May 3 at 9:48 AM logoMerrimack Announces Timing of First Quarter 2017 Investor Conference Call - PR Newswire (press release) - May 3 at 8:20 AM logoMerrimack Announces Timing of First Quarter 2017 Investor Conference Call - May 2 at 7:51 PM logoMerrimack Pharmaceuticals Inc (MACK) Given Average Rating of "Hold" by Analysts - May 2 at 2:48 PM logoMerrimack Pharmaceuticals Inc (MACK) Downgraded by Zacks Investment Research - May 2 at 1:56 PM logoSomewhat Positive Media Coverage Very Unlikely to Impact Merrimack Pharmaceuticals (MACK) Stock Price - April 27 at 11:38 PM logoWhat's in the Cards for Merrimack (MACK) in Q1 Earnings? - April 27 at 6:57 PM logoMerrimack Pharmaceuticals (MACK) Getting Somewhat Favorable Media Coverage, Study Finds - April 23 at 8:55 PM



Merrimack Pharmaceuticals (MACK) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff